Podcasts

Episode 46 | Navigating Resistance in ALK-Positive NSCLC Patients on TKI Therapy

Dr Rebecca Tay is joined by Professor Ben Solomon and A/Prof Michael Ng to discuss clinical and genetic factors affecting treatment choice for ALK-Positive NSCLC patients on TKI therapy.

Episode Summary

We have witnessed incredible advances in therapy since ALK was discovered in 2007, starting from the pivotal PROFILE 1001 study of crizotinib in advanced ALK positive NSCLC to present day where we now have five approved targeted agents, with increasing potency, selectivity and CNS activity with each successive generation of drug. Despite these advances in therapy, the emergence of treatment resistance in the TKI still remains one of greatest challenges in the clinic. Our TOGA podcast panel discuss the clinical and genetic factors affecting treatment choice, sequencing and resistance patterns, including oligoprogression and local therapy considerations.

Show Hosts

Dr Rebecca Tay, Medical Oncologist at Royal Hobart Hospital and ICON Hobart
Professor Ben Solomon, Medical Oncologist at Peter MacCallum Cancer Centre & Board member, Scientific Chair of TOGA
Associate Professor Michael Ng, Radiation Oncologist at GenesisCare St Vincents Hospital Melbourne and Head of Stereotactic Radiotherapy at GenesisCare Victoria

References

CROWN
Gomez paper denovo oligomet SABR
Kroeze – concurrent systemic therapy + SABR consensus
Tsai Curb trial RCT for oligoprogression

Play Episode 46 | Navigating Resistance in ALK-Positive NSCLC Patients on TKI Therapy

More Podcasts

51 – Vaccines in Thoracic Oncology: The Next Frontier in Immunotherapy

Podcasts
May 9, 2025

In this episode, Prof Tom John, Prof Georgina Long AO, and Prof Ken O'Byrne delve into technological advances spurred by COVID-19 vaccine development, promising results

50 – The Role of Liquid Biopsy in Modern Oncology

Podcasts
March 21, 2025

In this episode, Dr. Malinda Itchins, Dr. Annie Wong, and A/Prof Steven Kao discuss the concept of liquid biopsy, its advantages and limitations, and its

49 – Exploring EGFR Exon 20 Insertion Mutations

Podcasts
March 7, 2025

In this episode of Conversations in Lung Cancer Research, A/Prof Mel Moore, along with thoracic oncologists Dr. Malinda Itchins and A/Prof Surein Arulananda, delve into

48 – A Conversation with Prof. Michael Boyer

Podcasts
February 6, 2025

In this episode of Conversations in Lung Cancer Research, A/Prof Mel Moore interviews Prof Michael Boyer, AM about his extensive career in medical oncology and

47 – Introducing Conversations in Lung Cancer Research

Podcasts
February 6, 2025

In this introductory episode, A/Prof Mel Moore, announces the evolution of TOGA podcasts to 'Conversations in Lung Cancer Research.'

45 – The Case For IO in Early-Stage NSCLC in a Once in a Lifetime World

Podcasts
December 2, 2024

Dr Deme Karikios is joined by Dr Lauren Brown and Dr Stephen Barnett to discuss IO in early-stage NSCLC in the Australian context.

Join our community – stay up to date with the latest research, TOGA news and events

The Thoracic Oncology Group of Australasia Limited acknowledges Traditional Owners of Country throughout Australia and recognises the continuing connection to lands, waters and communities. We pay our respect to Aboriginal and Torres Strait cultures; and to Elders past and present.

Contact

PO Box 1103
Thornbury VIC 3071
Ph: +61 3 9087 3550
ABN: 47 641 984 198

TOGA

Quicklinks

Thoracic Oncology Group of Australasia is registered with the Australian Taxation Office as an Income Tax Exempt Charitable Entity. Donations $2 and over are tax deductible.